Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study.
about
A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in UgandaLow dose versus high dose stavudine for treating people with HIV infectionToxicity associated with stavudine dose reduction from 40 to 30 mg in first-line antiretroviral therapyIncidence and predictors of first line antiretroviral regimen modification in western KenyaPlasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART).Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional studyLIPODYSTROPHY SYNDROME IN HIV-INFECTED CHILDREN ON HAART.Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South AfricaAntiretroviral Therapy, Especially Efavirenz, Is Associated with Low Bone Mineral Density in HIV-Infected South Africans.Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection.High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study.Effects of a reduced dose of stavudine on the incidence and severity of peripheral neuropathy in HIV-infected adults in South AfricaIncreases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South AfricaContinuous antiretroviral therapy decreases bone mineral density.Estimation of intracellular concentration of stavudine triphosphate in HIV-infected children given a reduced dose of 0.5 milligrams per kilogram twice daily.Long term adverse effects related to nucleoside reverse transcriptase inhibitors: clinical impact of mitochondrial toxicity.Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142.Therapeutic drug monitoring in highly active antiretroviral therapy.Bone mineral density in HIV-infected women taking antiretroviral therapy: a systematic review.From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir.Metabolic Complications and Glucose Metabolism in HIV Infection: A Review of the Evidence.Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.Effect of Antiretroviral Therapy on Bone and Renal Health in Young Adults Infected With HIV in Early Life.A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients.Antiretroviral therapy and pregnancy: effect on cortical bone status of human immunodeficiency virus-infected Caucasian women as assessed by quantitative ultrasonography.Substituting Abacavir for Stavudine in Children Who Are Virally Suppressed Without Lipodystrophy: Randomized Clinical Trial in Johannesburg, South Africa.
P2860
Q21559730-33685AB2-A96B-4A38-8423-D29F2F9922A3Q24186488-9EBC525D-F463-4BF4-9440-B2EEC7A300C0Q28478110-716ED48F-BDC4-40DA-804A-EF1376FDAB3BQ28541822-8B13968B-DF0E-4E5E-934B-0754EDEB5C31Q33600363-11EEAA68-4BB6-4549-ACFD-91E174F16B88Q34039225-5F60B385-A1F8-4625-92D2-51D8931446E5Q34058478-E28A8406-46D4-4216-A3C5-BAFBD3A429AEQ35856520-1289694D-9950-492D-959F-11FCCDA5D9D6Q35859876-54B66A2C-C89B-40F6-9B10-60E57FA5286DQ36097686-6D3D9B68-1FD6-4EFC-BE08-95E8FFBB381FQ36646867-B4D17894-9229-4FB6-AE51-DF328BC09497Q36870758-FF536197-D174-4ADB-9838-B6B845246E9CQ37330398-BDEF228E-5C74-43B1-806D-DF5690860B97Q37357149-9BDA010D-0860-4E22-A5E9-2C2730EC36E1Q37544710-3A7637EC-F0E7-477A-802B-FDD4B89109C7Q37634512-C25D8647-5CB8-4022-A3FE-31E353B643F9Q37641866-4A8742B2-BB19-4632-9714-63F8BC7CCC15Q37720765-0010E2CC-5669-43D0-A130-B2DBDF2E5CE3Q37756578-A9C75671-EE9B-4525-A7E9-506ABF95BA5FQ37828539-9FD5C07A-6506-47FA-916C-DB19E7AF4947Q38931905-73F7AE4F-D5ED-4C55-B8A2-C9F6F182C1EAQ39043026-E6AB5FF3-5AA2-4ABC-8DEA-E29D727A06B7Q40203598-2FD77242-408D-4349-8AAA-238DE0C991EAQ42249729-023D58E0-EAC2-4EA2-988C-32FCC028889BQ42279253-CC6A19DF-330E-46EF-A071-40912AC2AC1BQ47548671-3D2EA9E6-7070-42B6-873A-E1FA219EA1EB
P2860
Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Effect of reducing the dose of ...... randomized, controlled study.
@ast
Effect of reducing the dose of ...... randomized, controlled study.
@en
type
label
Effect of reducing the dose of ...... randomized, controlled study.
@ast
Effect of reducing the dose of ...... randomized, controlled study.
@en
prefLabel
Effect of reducing the dose of ...... randomized, controlled study.
@ast
Effect of reducing the dose of ...... randomized, controlled study.
@en
P2093
P2860
P356
P1476
Effect of reducing the dose of ...... randomized, controlled study.
@en
P2093
D Lebrecht
G A McComsey
M O'Riordan
U A Walker
P2860
P304
P356
10.1086/529384
P407
P577
2008-04-01T00:00:00Z